Showing results (301-310 of 377) with videos related to
Sort By:
Pageof 38
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 20, 2022
Diagnostic criteria for acute-on-chronic liver failure and related disease conditions in JapanSatoshi Mochida, Nobuaki Nakayama, Shuji Terai, et al.Journal of Gastroenterology|November 23, 2016
The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III studyHiromitsu Kumada, Yoshiyuki Suzuki, Yoshiyasu Karino, et al.BMJ (Clinical Research Ed.)|August 12, 2025
Effectiveness of screening and ultra-brief intervention for hazardous drinking in primary care: pragmatic cluster randomised controlled trialRyuhei So, Kazuya Kariyama, Shunsuke Oyamada, et al.Journal of Clinical Medicine|February 26, 2025
Real-World Setting of Efficacy and Safety of 3 Years of Rifaximin Administration in Japanese Patients with Hepatic Encephalopathy: A Multicenter Retrospective StudyHideto Kawaratani, Tadashi Namisaki, Yasuteru Kondo, et al.International Journal of Oncology|February 11, 2005
Comparison study of the expressions of myristoylated alanine-rich C kinase substrate in hepatocellular carcinoma, liver cirrhosis, chronic hepatitis, and normal liverTsutomu Masaki, Masaaki Tokuda, Shuhei Yoshida, et al.BMC Gastroenterology|January 21, 2018
Treatment of long-segment Barrett's adenocarcinoma by complete circular endoscopic submucosal dissection: a case reportMiki Kaneko, Akira Mitoro, Motoyuki Yoshida, et al.Cancer Science|July 28, 2020
A randomized, double-blind, placebo-controlled, phase 3 study of tivantinib in Japanese patients with MET-high hepatocellular carcinomaMasatoshi Kudo, Manabu Morimoto, Michihisa Moriguchi, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 3, 2025
Prognostic significance of skeletal muscle mass in patients with alcohol-related cirrhosisAkihiko Shibamoto, Tadashi Namisaki, Satoshi Iwai, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|December 29, 2016
Combined treatment with dipeptidyl peptidase-4 inhibitor (sitagliptin) and angiotensin-II type 1 receptor blocker (losartan) suppresses progression in a non-diabetic rat model of steatohepatitisYasushi Okura, Tadashi Namisaki, Kei Moriya, et al.Journal of Clinical Medicine|November 13, 2021
The Combination of Albumin-Bilirubin Score and Prothrombin Time Is a Useful Tool for Predicting Liver Dysfunction after Transcatheter Arterial Chemoembolization in Child-Pugh Class A Patients with Hepatocellular Carcinoma within Up-to-Seven CriteriaHiroaki Takaya, Tadashi Namisaki, Soichi Takeda, et al.Pageof 38